What are the most common side effects of OLANZAPINE AND FUOXETINE?

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for OLANZAPINE AND FUOXETINE. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Is OLANZAPINE AND FUOXETINE the same as Olanzapine and Fluoxetine?

Olanzapine and Fluoxetine is a brand name for OLANZAPINE AND FUOXETINE. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

OLANZAPINE AND FUOXETINE

Q: What is OLANZAPINE AND FUOXETINE used for?

OLANZAPINE AND FUOXETINE (brand name Olanzapine and Fluoxetine) is a Atypical Antipsychotic indicated for an atypical antipsychotic and fluoxetine, a selective serotonin reuptake inhibitor, indicated for treatment of: Acute Depressive Episodes Associated with Bipolar I Disorder ( 1 ) Treatment Resistant Depression ( 1 ).

Q: How does OLANZAPINE AND FUOXETINE work?

OLANZAPINE AND FUOXETINE works through the following mechanism: 12.1 Mechanism of Action The mechanism of action of olanzapine and fluoxetine in the listed indications, is unclear. However, the combined effect of olanzapine and fluoxetine at the monoaminergic neural systems (serotonin, norepinephrine, and dopamine) could be responsible for the pharmacological effect..

Atypical Antipsychotic

Brand names: Olanzapine and Fluoxetine

Oral

Mechanism of Action

12.1 Mechanism of Action The mechanism of action of olanzapine and fluoxetine in the listed indications, is unclear. However, the combined effect of olanzapine and fluoxetine at the monoaminergic neural systems (serotonin, norepinephrine, and dopamine) could be responsible for the pharmacological effect.

Indications

an atypical antipsychotic and fluoxetine

a selective serotonin reuptake inhibitor

indicated for treatment of: Acute Depressive Episodes Associated with Bipolar I Disorder ( 1 ) Treatment Resistant Depression ( 1 )

Contraindications

• 4 CONTRAINDICATIONS Monoamine Oxidase Inhibitors (MAOI) : Because of the risk of serotonin syndrome
• do not start olanzapine and fluoxetine capsules in a patient who is being treated with linezolid or intravenous methylene blue. (4.1) P imozide : Do not use. Risk of QT interval prolongation (4.2
• 5.20
• 7.7
• 7.8) Thioridazine : Do not use. Risk of QT interval prolongation. Do not use thioridazine within 5 weeks of discontinuing olanzapine and fluoxetine capsules (4.2

FDA Warnings

5 WARNINGS AND PRECAUTIONS Neuroleptic Malignant Syndrome : Manage with immediate discontinuation and close monitoring ( 5
5 ) H y perg lycemia and Diabetes Mellitus : In some cases extreme and associated with ketoacidosis or hyperosmolar coma or death
If concomitant use of olanzapine and fluoxetine capsules with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases (5
Risk is increased during initial dose titration

Known Side Effects

8 documented side effects by frequency

Drug Not Working

>10%

Weight Gain

>10%

Drowsiness

1-10%

Nausea

1-10%

Fatigue

1-10%

Anxiety

1-10%

Vomiting

1-10%

Condition Worsened

0.1-1%

Community Discussions

No community discussions found for OLANZAPINE AND FUOXETINE yet.

Primary sources

Every figure on this page links back to its primary source. See data sources for full provenance.

DailyMed FDA label search → OLANZAPINE AND FUOXETINE openFDA label JSON → OLANZAPINE AND FUOXETINE FAERS adverse-event reports → OLANZAPINE AND FUOXETINE ClinicalTrials.gov → completed Phase 2+ trials of OLANZAPINE AND FUOXETINE

Compare With

15 available comparisons

Formulations

Dosage Forms

Tablet

Route

Oral